These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9632367)

  • 1. Auxiliary agents for the peroral administration of peptide and protein drugs: synthesis and evaluation of novel pepstatin analogues.
    Kratzel M; Hiessböck R; Bernkop-Schnürch A
    J Med Chem; 1998 Jun; 41(13):2339-44. PubMed ID: 9632367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified pepstatins: synthesis and evaluation of N-terminally modified analogues.
    Kratzel M; Schlichtner B; Kirchmayer R; Bernkop-Schnürch A
    J Med Chem; 1999 Jun; 42(11):2041-5. PubMed ID: 10354412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, development and in vitro evaluation of drug delivery systems with protective effect against degradation by pepsin.
    Bernkop-Schnürch A; Kirchmayer R; Kratzel M
    J Drug Target; 1999; 7(1):55-63. PubMed ID: 10614815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
    Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
    Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valaminols, probably the most simplified peptide-analogs acting as pepsin inhibitors.
    Kratzel M; Bernkop-Schnürch A
    Peptides; 2000 Feb; 21(2):289-93. PubMed ID: 10764958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
    Salas E; Ramírez A; Otero-Bilbao A; Vázquez R; Reyes O; Mendiola J; Duarte CA; Otero-González A; Gutiérrez OA; Chávez MA
    J Pharm Biomed Anal; 2004 Mar; 34(4):833-40. PubMed ID: 15019062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the synthetic route to pepstatin analogues by SPPS using O-protected and O-unprotected statine as building blocks.
    Cadicamo CD; Asante V; Abu Ammar M; Borelli C; Korting HC; Koksch B
    J Pept Sci; 2009 Apr; 15(4):272-7. PubMed ID: 19189272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan--a review.
    George M; Abraham TE
    J Control Release; 2006 Aug; 114(1):1-14. PubMed ID: 16828914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
    Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
    Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin.
    Rich DH; Sun ET; Ulm E
    J Med Chem; 1980 Jan; 23(1):27-33. PubMed ID: 6767029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin.
    Rich DH; Bernatowicz MS
    J Med Chem; 1982 Jul; 25(7):791-5. PubMed ID: 6809942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activity of new conformationally restricted analogues of pepstatin.
    Szewczuk Z; Rebholz KL; Rich DH
    Int J Pept Protein Res; 1992; 40(3-4):233-42. PubMed ID: 1478780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the oral route possible for peptide and protein drug delivery?
    Morishita M; Peppas NA
    Drug Discov Today; 2006 Oct; 11(19-20):905-10. PubMed ID: 16997140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-assembled monolayer of a pepstatin fragment as a sensing element for aspartyl proteases.
    Kitano H; Makino Y; Kawasaki H; Sumi Y
    Anal Chem; 2005 Mar; 77(6):1588-95. PubMed ID: 15762561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic barriers for GI peptide and protein delivery.
    Woodley JF
    Crit Rev Ther Drug Carrier Syst; 1994; 11(2-3):61-95. PubMed ID: 7600588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein.
    Corradin S; Ransijn A; Corradin G; Bouvier J; Delgado MB; Fernandez-Carneado J; Mottram JC; Vergères G; Mauël J
    Biochem J; 2002 Nov; 367(Pt 3):761-9. PubMed ID: 12137567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative delivery systems for peptides and proteins as drugs.
    Eppstein DA; Longenecker JP
    Crit Rev Ther Drug Carrier Syst; 1988; 5(2):99-139. PubMed ID: 3052876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional matrices for oral peptide delivery.
    Bernkop-Schnürch A; Walker G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3.
    Ng KK; Petersen JF; Cherney MM; Garen C; Zalatoris JJ; Rao-Naik C; Dunn BM; Martzen MR; Peanasky RJ; James MN
    Nat Struct Biol; 2000 Aug; 7(8):653-7. PubMed ID: 10932249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.